• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Research Briefing on 4-(chlorodifluoromethoxy)phenylmethanol (CAS: 50823-88-6): Recent Advances and Applications

4-(chlorodifluoromethoxy)phenylmethanol (CAS: 50823-88-6) is a fluorinated aromatic alcohol that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug development. This compound, characterized by the presence of a chlorodifluoromethoxy group and a phenylmethanol moiety, serves as a versatile intermediate in the synthesis of various bioactive molecules. Recent studies have explored its utility in the design of novel therapeutic agents, particularly in the context of anti-inflammatory, antimicrobial, and anticancer applications.

One of the most notable advancements in the research of 4-(chlorodifluoromethoxy)phenylmethanol is its role as a key intermediate in the synthesis of fluorinated analogs of biologically active compounds. Fluorination is a common strategy in medicinal chemistry to enhance the metabolic stability, bioavailability, and binding affinity of drug candidates. The chlorodifluoromethoxy group in this compound provides a unique handle for further chemical modifications, enabling the development of derivatives with tailored pharmacological properties. Recent publications have highlighted its use in the synthesis of fluorinated tyrosine kinase inhibitors and G-protein-coupled receptor (GPCR) modulators, which are of great interest in targeted cancer therapies and neurological disorders.

In addition to its synthetic utility, 4-(chlorodifluoromethoxy)phenylmethanol has been investigated for its direct biological activities. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory effects against cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes. The study reported that the introduction of the chlorodifluoromethoxy group significantly enhanced the selectivity and potency of the inhibitors compared to their non-fluorinated counterparts. These findings underscore the potential of 4-(chlorodifluoromethoxy)phenylmethanol as a scaffold for developing next-generation anti-inflammatory drugs.

Another area of active research involves the antimicrobial properties of 4-(chlorodifluoromethoxy)phenylmethanol derivatives. A recent preprint on bioRxiv detailed the synthesis and evaluation of a series of fluorinated phenylmethanol derivatives against multidrug-resistant bacterial strains. The results indicated that the chlorodifluoromethoxy moiety contributed to improved membrane permeability and target engagement, leading to enhanced antibacterial activity. These insights are particularly relevant in the context of the growing global threat of antibiotic resistance, as they provide a foundation for designing new antimicrobial agents with novel mechanisms of action.

Despite these promising developments, challenges remain in the optimization and clinical translation of 4-(chlorodifluoromethoxy)phenylmethanol-based compounds. Issues such as metabolic stability, toxicity profiles, and scalable synthesis need to be addressed to fully realize their therapeutic potential. Ongoing research efforts are focused on leveraging advanced computational modeling and high-throughput screening to identify optimal derivatives with favorable pharmacokinetic and safety profiles. Collaborative initiatives between academic institutions and pharmaceutical companies are also underway to accelerate the development of these compounds into viable drug candidates.

In conclusion, 4-(chlorodifluoromethoxy)phenylmethanol (CAS: 50823-88-6) represents a promising scaffold in medicinal chemistry, with demonstrated applications in anti-inflammatory, antimicrobial, and anticancer drug discovery. Recent studies have shed light on its synthetic versatility and biological activities, paving the way for future innovations. As research in this area continues to evolve, it is anticipated that this compound and its derivatives will play an increasingly important role in addressing unmet medical needs and advancing the field of chemical biology.

• 147992-34-5(4-(chlorodifluoromethoxy)benzoic acid)
• 1404194-47-3(2-[Chloro(difluoro)methoxy]-1,3-dimethyl-benzene)
• 89807-44-3(Benzene, 1-(chlorodifluoromethoxy)-4-(chloromethyl)-)
• 1404195-03-4(2-[Chloro(difluoro)methoxy]-1,4-dimethyl-benzene)
• 50823-89-7(.)
• 175838-99-0(1,1'-Biphenyl, 4-(chlorodifluoromethoxy)-)
• 959249-99-1(3-(chlorodifluoromethoxy)benzoic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)